Education
- PhD - Humboldt University, Berlin - 1992
Research Interests
Dr. Oesterreich's research is focused on endocrine resistance in breast cancer, including the analysis of aberrant genetic and epigenetic changes. She utilizes cell line models, mouse models, and clinical samples. More recently her group has begun to study the role of nuclear receptors including ER and PR in ovarian cancer development and progression.
Awards and Honors
- HOECHST PhD Award - 1990
- Deutscher Akademischer Austauschdienst Fellowship – 1992
- German Academic Exchange Fellowship
- Postdoctoral Fellowship, Susan G. Komen Breast Cancer - 1993
- Howard Hughes Medical Institute, New Faculty Start-Up - 1997
- Howard Temin (K01), Career Development Award (NIH/NCI) - 1999
- T.T. Chao Scholar Award - 2000
- Women's Health Research Award (Women in Endocrinology) - 2002
- Alexander von Humboldt Fellowship - 2006
Selected Publications
View Dr. Oesterreich's publications on PubMed
Pathiraja TN, Shetty TB, Jelinek J, He R, Hartmaier R, Margossian AL, Hilsenbeck SG, Issa JP, Oesterreich S. Progesterone receptor isoform-specific promoter methylation - Association of PRA methylation with worse outcome in breast cancer patients. Clin Cancer Res. 17:4177-4186. 2011. PMID: 21459801
Lachapelle S, Oesterreich S, Lebel M. Loss of the helicase function of the Werner gene product increases perinatal lethality of mice lacking the Scaffold Attachment Factor B1 and inhibits mouse embryonic fibroblast immortalization. Aging. 3:277-290. 2011. PMID: 21464516.
Casa AJ, Potter AS, Malik S, Lazard Z, Kuiatse I, Kim HT, Tsimelzon A, Creighton CJ, Hilsenbeck SG, Brown PH, Oesterreich S, Lee AV. Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat. 2012 Feb; 132(1):61-73. PMID: 21541704
Garee JP, Meyer R, Oesterreich S. Co-repressor activity of scaffold attachment factor B1 requires sumoylation. Biochem Biophys Res Commun. 2011 May 20;408(4):516-22. PMID: 21527249
Hartmaier RJ, Richter AS, Gillihan RM, Sallit JZ, McGuire SE, Wang J, Lee AV, Osborne CK, O'Malley BW, Brown PH, Xu J, Skaar TC, Philips S, Rae JM, Azzouz F, Li L, Hayden J, Henry NL, Nguyen AT, Stearns V, Hayes DF, Flockhart DA, Oesterreich S. A SNP in Steroid Receptor Coactivator-1 Disrupts a GSK3? Phosphorylation Site and Is Associated with Altered Tamoxifen Response in Bone. Mol Endo 2012 26(2):220-7. PMID: 22174377
Watters RJ, Benos PV, Oesterreich S. To bind or not to bind - FoxA1 determines estrogen receptor action in breast cancer progression. Breast Cancer Res.14(3):312. 2012. PMID: 22713214
Cerne JZ, Zong L, Jelinek J, Hilsenbeck SG, Wang T, Oesterreich S, McGuire SE. BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients. Breast Cancer Res Treat. 2012 Jun 16 135(1): 135-43. PMID: 22706629
Philips S, Rae JM, Oesterreich S, Hayes DF, Stearns V, Henry NL, Storniolo AM, Flockhart DA, Skaar TC. Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes. Front Pharmacol. 2012;3:54. PMID: 22479249
Osmanbeyoglu HU, Hartmaier RJ, Oesterreich S, Lu X. Improving ChIP-seq peak-calling for functional co-regulator binding by integrating multiple sources of biological information. BMC Genomics. 13 Suppl 1:S1. 2012 PMID: 22369349
Smith CL, Migliaccio I, Chaubal V, Wu MF, Pace MC, Hartmaier R, Jiang S, Edwards DP, Gutiérrez MC, Hilsenbeck SG, Oesterreich S. Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence. Breast Cancer Res Treat 2012 Nov; 136:253-65. PMID 23015261
Steinman RA, Brufsky AM, Oesterreich S. Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment? Breast Cancer Res 2012 14(5):213; PMID 23014660
Coronnello C, Hartmaier R, Arora A, Huleihel L, Pandit KV, Bais AS, Butterworth M, Kaminski N, Stormo GD, Oesterreich S, Benos PV. Novel Modeling of Combinatorial miRNA Targeting Identifies SNP with Potential Role in Bone Density. PLoS Comput Biol 2012 8(12):e1002830. PMID 23284279
Henry NL, Skaar TC, Dantzer J, LiL, Kidwell K, Gersch C, Nguyen AT, Rae JM, Desta Z, Oesterreich S, Phillips S, Carpenter JS, Storniolo AM, Stearns V, Hayes DF, Flockhart DA. Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer. Breast Cancer Res Treat 2013 April 138(3):807-16. PMID 23546553
Hernández- Hernández JM, Mallappa C, Nasipak BT, Oesterreich S, Imbalzano AN. The Scaffold attachment factor b1 (Safb1) regulates myogenic differentiation by facilitating the transition of myogenic gene chromatin from a repressed to an activated state. Nucleic Acids Res 2013 Jun 4(11):5704-16. PMID: 23609547
Oesterreich S, Edwards R, Vlad A. Progestins: Pro-senescence therapy for ovarian cancer? Cell Cycle. 2013 Jun 12(11): 1662-3. PMID:23708445
Mukhopadhyay NK, Kim J, You S, Morello M, Hager MH, Huang WC, Ramachandran A, Yang J, Cinar B, Rubin MA, Adam RM, Oesterreich S, Di Vizio D, Freeman MR. Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2. Oncogene 2013 Jul 29 [Epub ahead of print] PMID 23893242
Oesterreich S, Brufsky AM, Davidson NE. Using Mice to Treat (Wo)men: Mining Genetic Changes in Patient Xenografts to Attack Breast Cancer. Cell Rep 2013 Sep 26; 4(6):1061-2. PMID: 24075202
Oesterreich S, Davidson NE. The search for ESR1 mutations in breast cancer. Nat Genet. 2013 Dec; 45(12):1415-6 PMID: 24270445
Sikora MJ, Cooper KL, Bahreini A, Luthra S, Wang G, Chandran UR, Davidson NE, Dabbs DJ, Welm AL, Oesterreich S. Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. Cancer Res. 2014 Mar 1; 74(5):1463-74. PMID: 24425047
Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jelinek J, Issa JP, Richer JK, Elias A, McIlroy M, Young L, Davidson NE, Schiff R, Li W, and Oesterreich S. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Science Transl Med. 2014 Mar 26; 6(229):229ra41. PMID: 24670685